Investment Rating - The report maintains a "Buy" rating for the company [6][12]. Core Insights - The company reported a revenue of 1.852 billion RMB for 2025, with an adjusted loss of 389 million RMB. The operating cash flow was positive at 195 million RMB, marking three consecutive years of positive operating cash flow. The company has a strong cash position with 3.325 billion RMB in cash and bank deposits [2]. - The B7H3 ADC is entering a critical clinical phase, with expectations for commercialization of the HER2 ADC in 2026. The company has 10 ADCs in clinical stages, with over 3,200 patients enrolled, highlighting its international expansion [3][4]. - The core pipeline B7H3 ADC is advancing in Phase 3 clinical trials for metastatic castration-resistant prostate cancer. The median rPFS is reported at 11.3 months, with a median OS of 22.5 months for previously treated patients [4]. - The company has a rich pipeline of ADC innovations, with multiple data readouts expected in 2026, including clinical data for various ADC combinations in different cancer types [5]. Financial Projections - Revenue projections for 2026, 2027, and 2028 are 1.972 billion RMB, 2.100 billion RMB, and 2.635 billion RMB, respectively, with growth rates of 6.5%, 6.5%, and 25.5% [6][12]. - The projected net loss for 2026, 2027, and 2028 is expected to be 354 million RMB, 316 million RMB, and 187 million RMB, respectively [6][12]. - The earnings per share (EPS) for the same years are projected to be -3.92 RMB, -3.51 RMB, and -2.08 RMB [6][12].